Hepatitis & Liver Infections Questions

Hepatitis A and E spread through contaminated water and food — usually cause short illness that resolves. Hepatitis B and C spread through blood, sexual contact, and (for B) mother to child — can become chronic and cause liver cirrhosis or cancer. Hepatitis D only occurs with B. Vaccines exist for A and B, not for C. Testing for hepatitis B is worth doing at least once in adulthood; C testing is recommended for anyone with risk factors.

Through blood (needle sharing, unscreened blood transfusions, tattoos and piercings with unsterile equipment), sexual contact, and from mother to baby at birth. It doesn't spread through casual contact, sharing food, or coughing. India has significant hepatitis B prevalence — the childhood vaccine has reduced this dramatically but many adults born before universal vaccination remain unvaccinated.

Yes — modern direct-acting antiviral drugs cure over 95% of hepatitis C cases with 8-12 weeks of oral medication. This is one of the biggest treatment advances of the last decade. The challenge is finding people who have it, since it's silent for years. Anyone with risk factors (blood transfusion before 2001, injection drug use, healthcare exposure, tattoos with unsterile equipment) should get tested.

Most people don't — chronic hepatitis is silent for years. Vague symptoms like fatigue, poor appetite, or mild upper right abdominal discomfort may appear late. Diagnosis is by blood test (hepatitis B surface antigen, hepatitis C antibody). Anyone with elevated liver enzymes on a routine test, or with risk factors, should be tested. Early diagnosis lets treatment start before serious liver damage.

Yes — for hepatitis B, close family members (spouse, children, and household contacts) should be tested and vaccinated if negative. For hepatitis C, testing sexual partners and anyone who shared needles is recommended. Casual household contact doesn't spread these viruses; children shouldn't be treated differently at home. Awareness prevents transmission and enables early treatment.

Modern malaria RDTs have sensitivity of roughly 90-95% for detecting Plasmodium falciparum at typical fever-onset parasite levels, meaning they catch most cases but can miss around 5-10%. Sensitivity for P. vivax is lower, around 80-90%, because the antigens vary more across strains. Sensitivity drops significantly when parasite counts are very low (early in the illness or in asymptomatic carriers). Blood smear microscopy remains the gold standard, with sensitivity approaching 95% in expert hands and the ability to identify species and quantify parasite load. In practice, RDT is the fast first test almost anywhere in India; blood smear confirms the diagnosis and guides treatment intensity. A negative RDT with persistent malaria-suggestive symptoms should always trigger a follow-up smear rather than being taken as definitive.

BCG (Bacillus Calmette-Guérin) vaccine has real but limited effectiveness. It reliably prevents severe childhood forms of TB. TB meningitis and disseminated (miliary) TB, with efficacy of 60-80%. It is far less effective at preventing adult pulmonary TB, with published efficacy ranging from 0% to 80% depending on the population studied, the variability itself is a major research puzzle, possibly related to prior exposure to environmental mycobacteria in different geographies. Despite this variability, India continues universal BCG vaccination at birth because the severe childhood TB prevention justifies it in a high-burden country; deaths from meningitis or miliary TB in unvaccinated Indian infants would be substantial. Improved TB vaccines are in active development globally (M72/AS01E is in phase 3 trials), but until one is approved, BCG remains standard for Indian newborns and provides genuine protection for the childhood forms that matter most in the neonatal period.

MDR-TB is TB resistant to at least isoniazid and rifampicin, the two most powerful first-line drugs. This resistance usually develops when patients receive inadequate treatment (wrong drugs, wrong doses, insufficient duration, or interruption), surviving bacteria multiply and become resistant. XDR-TB (extensively drug-resistant TB) is even more resistant, adding resistance to fluoroquinolones and injectable second-line drugs. India has among the largest number of MDR-TB cases globally. Treatment takes 9-24 months (vs 6 months for drug-sensitive TB), involves 4-7 medications simultaneously, causes more side effects, costs significantly more, and has lower cure rates (roughly 60-75% vs 85-95% for drug-sensitive TB). India's NTEP provides free MDR-TB diagnosis (GeneXpert MTB/RIF plus line probe assays) and treatment through dedicated DR-TB centres. Key patient rule: never stop TB treatment early even when feeling better, never skip doses, never take TB medications from unknown sources, creating MDR-TB harms both the patient and the community for decades.

The NS1 antigen appears in blood as early as day 1 of fever and stays detectable through roughly day 5-7. That is the window where NS1 is most sensitive. If you have fever with any classic dengue features, sudden high fever, severe body aches (especially behind the eyes), headache, nausea, or a rash, and you are anywhere in India during monsoon or early post-monsoon (June-November), ask your doctor about NS1 on the same day fever starts. Waiting past day 5 makes NS1 progressively less sensitive; after day 7, IgM antibody test becomes more useful. Testing on day 0-1 of fever occasionally gives false negatives because viral load has not yet peaked, a repeat test 24-48 hours later resolves this.

Three different things at three different time points. NS1 detects a viral protein made by the dengue virus itself, positive from day 1-7, catches active infection early. IgM antibody appears from day 5-7 onwards and stays positive for 2-3 months, catches recent infection, useful when NS1 window has passed. IgG antibody appears from day 7-14 and stays positive for years, indicates past infection or immunity, not useful for diagnosing current fever alone. In practice, doctors often order NS1 + IgM together in the first week of fever, since together they cover the whole infection window. IgG is only useful in specific situations like distinguishing primary vs secondary dengue (secondary infection has higher risk of severe dengue).

A positive NS1 confirms dengue and shifts the focus to monitoring for complications, since there is no antiviral treatment. Immediate steps your doctor will typically arrange: (a) baseline CBC to check platelet count and hematocrit; (b) monitoring platelet count daily during the critical phase (day 3-7 of fever), platelets can drop rapidly; (c) hydration guidance, oral or IV fluids as needed, particularly during the fever-defervescence phase which is when severe dengue often develops; (d) avoiding aspirin, ibuprofen, and other NSAIDs because they raise bleeding risk in dengue, paracetamol (acetaminophen) is the only safe antipyretic; (e) hospitalisation if warning signs appear (severe abdominal pain, persistent vomiting, bleeding from gums or nose, lethargy, cold extremities). The critical period is when fever breaks around day 4-6, that is the window to watch most carefully, not the fever itself.

A negative NS1 does not rule out dengue, especially in the first 24-48 hours of fever (viral load may not yet be at detectable levels) or after day 5-7 (NS1 window has closed). Practical next steps: (a) if you tested on day 1-2 of fever, repeat NS1 after 24-48 hours, sensitivity improves as viral load rises; (b) if fever has been going 5+ days, ask for IgM antibody test which becomes positive around day 5-7; (c) simultaneously rule out other Indian monsoon fevers with overlapping symptoms, malaria (blood smear + RDT), typhoid (Widal or blood culture), leptospirosis, chikungunya, and viral hepatitis all present similarly. Do not assume 'just viral fever' if fever continues past 48-72 hours without a diagnosis, return to your doctor for expanded workup rather than waiting it out at home.

NS1 (nonstructural protein 1) is a glycoprotein made by the dengue virus during its replication inside human cells. It is secreted into the bloodstream in large quantities from day 1 of infection, reaching detectable levels typically within 24 hours of fever onset and remaining detectable through roughly day 5-7. This early appearance makes NS1 uniquely useful because it fills the diagnostic gap before your body has produced detectable antibodies (IgM appears around day 5-7, IgG around day 7-14). NS1 is highly specific to flaviviruses (dengue, Zika, yellow fever), so a positive result in an Indian patient with fever during dengue season is almost certainly dengue, since Zika and yellow fever are rare here. Testing methods: ELISA is the lab standard (highest sensitivity); rapid diagnostic test (RDT) kits give point-of-care results in 15-30 minutes with slightly lower sensitivity.

Both detect the same NS1 antigen but differ in sensitivity, turnaround, and cost. NS1 ELISA (enzyme-linked immunosorbent assay): performed in a diagnostic laboratory, sensitivity typically 85-95%, results in 4-24 hours depending on lab batching, moderate cost. This is the standard reference test. NS1 rapid diagnostic test (RDT) kits: performed at point-of-care (clinic, small lab, some pharmacies), sensitivity typically 70-85%, results in 15-30 minutes, lower cost. RDTs are useful when time matters and lab access is limited, a positive RDT is highly reliable, but a negative RDT should ideally be confirmed with ELISA if clinical suspicion remains high. In India during dengue outbreaks, RDT-first-then-ELISA-if-negative is a common approach, particularly outside tier-1 cities where lab turnaround can slow the diagnosis.

In principle yes. NS1 tests can show cross-reactivity with other flaviviruses because these viruses share protein structures. In practice for Indian patients this is rarely a clinical issue: Zika virus is uncommon in India (small outbreaks reported), yellow fever is not endemic in India (a few imported cases), and Japanese encephalitis (JE) does exist but the clinical presentation differs enough that dengue vs JE is usually distinguishable clinically. For most Indian patients with fever and a positive NS1 test during dengue season, the result reliably indicates dengue. Where confusion can arise: recent yellow fever vaccination (given for international travel) or recent JE vaccination can occasionally cause transient antibody cross-reactivity, though this affects IgM tests more than NS1 antigen tests. If cross-reactivity is a genuine concern (post-travel, unusual clinical picture), confirmatory testing with dengue-specific PCR resolves it.

A negative NS1 test does not rule out dengue, it needs interpretation in context of when in the illness you tested. Common reasons for a false-negative NS1: (a) tested too early (first 24 hours of fever, viral load still rising below detection threshold); (b) tested too late (after day 5-7, NS1 has cleared from blood but antibodies are now present); (c) secondary dengue infection in someone previously infected with a different serotype, pre-existing IgG antibodies bind NS1 and reduce its detectability; (d) infection with certain P. vivax-like less common serotypes with lower NS1 production. Next steps for a symptomatic patient with negative NS1: repeat NS1 in 24-48 hours if still within day 1-5 window, or add IgM antibody test if past day 5, or PCR testing at a tertiary centre for definitive diagnosis. Do not accept 'ruled out dengue' from a single NS1 without considering timing, one test does not close the case if symptoms strongly suggest dengue.

The three anchor diagnoses in most cases: Hyperthermia related to underlying infection or inflammatory process (as evidenced by elevated body temperature above 38°C, warm skin, tachycardia); Deficient Fluid Volume or Risk for Deficient Fluid Volume related to excessive fluid loss from vomiting and insensible loss from fever (evidenced by decreased urine output, dry mucous membranes, tachycardia, hypotension); and Nausea related to gastrointestinal irritation, drug side effects, or central causes (evidenced by patient report and observed retching). Secondary diagnoses to consider based on presentation: Risk for Electrolyte Imbalance, Acute Pain (headache or abdominal), Imbalanced Nutrition Less than Body Requirements if vomiting is protracted, and Risk for Infection Transmission when the underlying cause is a communicable pathogen. Priority ordering follows Maslow, fluid balance first, then temperature, then comfort.

At minimum every 4-6 hours during the acute phase: temperature (route consistent, oral, axillary, or tympanic; note the route), heart rate, blood pressure (including orthostatic if the patient is ambulant), respiratory rate, oxygen saturation, level of consciousness, and pain score. Fluid balance: strict intake and output charting, urine specific gravity or colour observation, weight if possible daily at the same time. Vomiting characterisation: frequency, volume, colour and content (bilious, coffee-ground, undigested food, blood), and relation to food or medication. Assess mucous membranes, skin turgor, and capillary refill each shift for hydration status. In endemic Indian settings, note any petechiae, rash, or bleeding, early signs of severe dengue that shift the care plan significantly.

Establish IV access early, deteriorating patients can lose the option to hydrate orally quickly. Initiate rehydration per protocol (oral rehydration solution if tolerated; IV normal saline or Ringer's lactate if vomiting persists or dehydration is significant), correcting electrolyte deficits based on baseline labs. Administer prescribed antipyretic (paracetamol is first-line; avoid NSAIDs if dengue is on the differential due to bleeding risk) and prescribed antiemetic (ondansetron is common first-line for adults; metoclopramide alternatives). Cooling measures: tepid sponging if temperature is over 39°C, adequate exposure, ambient temperature control. Send off diagnostic samples early. CBC, electrolytes, urea/creatinine, urine routine, and pathogen-specific tests based on epidemiology (dengue NS1, malaria smear, typhoid Widal or blood culture, stool if diarrhoea present). Document baseline for evaluation.

Objective indicators of successful intervention within 24-48 hours: temperature trending down toward 37.5°C or lower without persistent antipyretic dependence; vomiting frequency reduced by at least 50%, patient tolerating small oral fluid volumes; urine output restored to at least 0.5 mL/kg/hour with clearing urine colour; heart rate and blood pressure normalising toward baseline; improving level of consciousness and patient-reported comfort. Red flags requiring escalation to the treating physician: persistent fever above 39°C beyond 48 hours of appropriate antipyretic use, worsening tachycardia despite fluid replacement, oliguria, altered mental status, new bleeding manifestations (particularly relevant in the Indian dengue season), rising creatinine, or persistent inability to tolerate oral intake. The care plan is not a static document, nursing diagnoses should be re-prioritised as the aetiology clarifies from diagnostic workup.

Neither. Malaria is caused by a single-celled parasite called Plasmodium, technically a protozoan, one of the oldest kinds of life on earth. Five species infect humans: P. falciparum (the most dangerous, common in Africa and parts of India's North-East and eastern states), P. vivax (the most widespread in India, causes relapsing infections), P. ovale, P. malariae, and P. knowlesi (rare, mainly South-East Asian forest exposure). Because it is a parasite and not a bacterium or virus, malaria does not respond to antibiotics or antiviral medicines. It needs specific antimalarial drugs, chloroquine, artemisinin-based combinations, or primaquine, depending on the species and drug-resistance pattern in the region.

The bite injects fewer than a hundred parasite sporozoites into your bloodstream, a tiny number, but they head straight for the liver within an hour. Inside a liver cell, each sporozoite multiplies silently over 7-30 days into tens of thousands of new parasites (merozoites). When the liver cell bursts, those merozoites flood into your bloodstream and start invading red blood cells. Each infected red cell then bursts every 48-72 hours, releasing more parasites, and this is when you first feel sick. So the mosquito bite is small, but the liver stage is a hidden multiplier that turns a handful of parasites into millions before symptoms even begin.

Because the parasite's blood-stage cycle is synchronised. All the infected red blood cells burst at roughly the same time, every 48 hours for P. vivax and P. ovale (tertian fever), 48 hours for P. falciparum (though often less regular), and 72 hours for P. malariae (quartan fever). Each mass rupture releases parasites plus toxic parasite waste products into the bloodstream, which triggers the immune system to spike fever, chills, and shivering, the classic malaria paroxysm. Between paroxysms, the parasite is quietly invading fresh red blood cells and you feel relatively normal. This cyclical pattern is so distinctive that a fever every other day in someone who has been in an endemic area should trigger a malaria test even before other symptoms develop.

Both P. falciparum and P. vivax are prevalent in India but they behave differently. P. falciparum is more common in Odisha, Chhattisgarh, Jharkhand, and the North-East and causes almost all severe and fatal malaria, cerebral malaria, kidney failure, ARDS, severe anaemia. It progresses fast and can kill within days if untreated. P. vivax is more widespread across the country and causes fewer deaths but has two features that matter: relapses can occur months to years after the original infection because dormant liver-stage parasites (hypnozoites) can reactivate, and chronic P. vivax weakens people over time. Any fever after being in a mosquito-endemic area should be tested regardless of which species is more common there, waiting to see if it is just viral fever can be dangerous with P. falciparum.

Getting infected and getting sick are two different things. Roughly one-third of the global population carries M. tuberculosis in latent form after some exposure, but only 5-10% ever develop active disease. Whether you progress from infection to active disease depends on multiple factors: immune status (HIV infection multiplies risk 20-30 times, diabetes doubles risk, aging weakens immunity), nutritional status (malnutrition dramatically increases risk), co-existing lung damage (smoking, silicosis, previous TB), genetic factors (specific HLA variants affect susceptibility), medications suppressing immunity (steroids, chemotherapy, TNF inhibitors), and the initial infecting dose. In India, the confluence of high HIV in some regions, high diabetes prevalence (over 100 million adults), household crowding, and undernutrition explains why India carries such a disproportionate share of the global TB burden despite decades of control efforts.

A positive RDT confirms malaria and shifts focus immediately to two things: (a) determining severity, a doctor evaluates whether it is uncomplicated malaria (treatable at home with oral antimalarials) or severe malaria (needs hospitalisation and IV artesunate). Severe malaria indicators include altered consciousness, seizures, jaundice, dark urine, breathing difficulty, or extreme weakness. (b) identifying species, this determines the drug regimen. For P. falciparum in India, artemisinin combination therapy (ACT) is first-line; for P. vivax, chloroquine plus primaquine (primaquine treats the dormant liver stage to prevent relapse). The doctor will also order a follow-up blood smear to quantify parasite load and check response to treatment at day 3. Do not self-treat with over-the-counter antimalarials on a positive RDT, the wrong drug or dose can drive resistance and worsen outcomes.

RDTs use protein-based antibodies that degrade at high temperatures, accuracy drops meaningfully when kits are stored above 30°C for extended periods, which is a real issue in Indian summers and in rural clinics without air conditioning. Storage above 40°C can produce false negatives even for kits well within their expiry date. Practical implications: kits held in unrefrigerated pharmacy shelves during peak summer months (April-June) may perform worse than the manufacturer's stated sensitivity; kits transported without cold-chain protection in field settings often lose reliability. This is why WHO recommends RDT lot testing before deployment in endemic areas. For patients: if an RDT result seems inconsistent with your clinical picture, ask for a blood smear rather than trusting the RDT alone, the smear does not have storage-related accuracy issues.

Malaria RDT kits are available in India but not typically sold for home use, they are meant for clinical or field-worker settings and are usually sold to hospitals, primary health centres, NGOs, and pharmacies for point-of-care testing rather than direct-to-consumer. Even where available at retail pharmacies, home use is not recommended because: interpreting a faint test line correctly needs practice, a negative result does not rule out early-stage malaria and needs follow-up, and any positive result immediately needs a doctor visit for treatment (antimalarials are prescription-only). Practical alternative: same-day RDT plus blood smear at a diagnostic lab or general practitioner clinic is inexpensive and available in most Indian cities. Do not delay treatment while trying to diagnose at home if you have symptoms consistent with malaria after mosquito exposure.

Latent TB means the M. tuberculosis bacteria are in your body but contained by your immune system inside granulomas, you have no symptoms, are not infectious, and cannot spread the disease. Chest X-ray is usually normal; TB is detected only through Mantoux test or IGRA blood test. Active TB means the bacteria have broken out of containment and are multiplying, causing symptoms (persistent cough, weight loss, night sweats, low-grade fever) and making you infectious to others. Roughly 5-10% of people with latent TB will develop active TB at some point in their lifetime, with the risk highest in the first 2 years after exposure and in anyone whose immune system weakens (HIV, diabetes, steroids, TNF inhibitors, aging). Whether latent TB needs treatment depends on individual risk. WHO recommends preventive treatment for household contacts of active TB cases, HIV-positive people, people starting immunosuppressive drugs, and healthcare workers with recent conversion. India's NTEP is expanding preventive TB treatment access, particularly for household contacts.

Ask for a peripheral blood smear as your primary test, thick smear for detection, thin smear for species identification. A rapid diagnostic test (RDT) is a reasonable add-on, especially if you are in a smaller clinic or evening hours when a microscopist may not be available; RDT gives a result in 15-20 minutes. If both are negative but fever and symptoms persist for another 24-48 hours, a repeat smear at a good centre or a PCR test at a tertiary hospital is the next step. Do not rely on RDT alone if your clinical picture is convincing, low-parasitemia infections and non-falciparum species (P. vivax, P. ovale) can be missed by rapid tests.

In government hospitals, both RDT and blood smear are typically free or nominal. In private labs, RDT and blood smear together are usually affordable and results come back the same day. RDT within 20-30 minutes, smear within 2-4 hours if the lab has a technician on shift. PCR is only available at larger hospitals and reference laboratories; it is significantly more expensive and takes 24-72 hours depending on the batch schedule. For anyone with fever in an endemic area, testing should not be delayed by cost, a delayed diagnosis in P. falciparum malaria can escalate to cerebral malaria within days.

A negative RDT does not rule out malaria, especially in the first 24-48 hours of illness or in P. vivax infection where parasite levels can be low. Next steps: (a) request a thick and thin blood smear read by an experienced microscopist, this is more sensitive than an RDT and identifies the species; (b) if smear is also negative but fever continues past 48 hours, repeat the smear, parasitemia rises with each fever cycle and can become detectable; (c) discuss PCR testing at a tertiary centre if smears remain negative but symptoms are strongly suggestive; (d) in parallel, work up other causes of fever in India, dengue, typhoid, chikungunya, leptospirosis, urinary infection, since these can co-exist or mimic malaria.

Very urgent, especially if you have travelled to sub-Saharan Africa, the Indian North-East, Odisha, Chhattisgarh, or parts of South-East Asia where P. falciparum is common. Get tested the same day. P. falciparum malaria can progress to severe disease within 24-72 hours of first symptoms, cerebral malaria, kidney failure, severe anaemia, ARDS. Tell the doctor exactly where you travelled, when, and whether you took prophylaxis. If travel was to a P. vivax or P. ovale region, symptoms can appear weeks to months after return because these species can lie dormant in the liver, any unexplained fever within a year of travel to an endemic zone warrants a malaria test, not just antibiotics for a presumed viral illness.

A negative test can be a real false-negative — the disease is there but the test missed it. The commonest reasons: parasite load is too low to detect (early infection, or partial treatment already given at home), the sample was taken between fever peaks when parasites are hiding inside cells, the RDT antigen has degraded due to bad storage, or the falciparum strain doesn't make HRP2 (a real problem in some African countries and now surfacing globally). Skill matters too — reading a blood smear well takes training. If clinical suspicion is high — persistent fever, recent travel to an endemic area, chills, jaundice — the doctor will repeat the smear every 12–24 hours for up to three days before ruling out malaria, or move to PCR. A single negative test is not enough to close the case.

No single blood test tells the whole story in COVID — CRP is best used alongside D-dimer, ferritin, LDH and lymphocyte count. CRP reflects general inflammation; D-dimer reflects clotting activity (raised D-dimer warns of pulmonary embolism, a serious COVID complication); ferritin often mirrors CRP but rises in inflammatory storms; LDH indicates tissue damage; and a dropping lymphocyte count is another warning sign of severe disease. Doctors combine these with oxygen level, respiratory rate, and CT chest findings to get a full picture. Age, kidney disease, obesity and chronic inflammation can all raise baseline CRP, so a single high value must always be interpreted alongside the clinical context — not as a stand-alone verdict.

Get to a hospital or clinic immediately — post-exposure treatment works best within 24 hours and must start within 7 days. If you've had a needlestick injury, unprotected sex with a known hepatitis B-positive partner, or any other significant exposure to blood or body fluids, wash the site with soap and water (do not squeeze or scrub), then go straight to an emergency department or occupational health service. The doctor will assess the exposure, test both you and (if possible) the source person, and decide what post-exposure prophylaxis (PEP) is needed based on your vaccination status. Delay reduces the chance PEP works — every hour matters, especially in the first 24. Don't wait for symptoms; hepatitis B often has no early signs but can still cause serious long-term liver damage.

PEP combines two things — a shot of hepatitis B immunoglobulin (HBIG) for immediate protection, plus the hepatitis B vaccine to build long-term immunity. HBIG contains ready-made antibodies against hepatitis B and starts protecting within hours; it's given as an intramuscular injection, ideally within 24 hours of exposure and no later than 7 days. The hepatitis B vaccine is started at the same time (in a different arm) and follows the standard 3-dose schedule (0, 1 and 6 months). If you've already completed the full vaccine series and have documented immunity, you may need only a booster or nothing at all. If you're only partially vaccinated, you finish the remaining doses along with HBIG. Follow-up antibody testing 1–2 months after the last dose confirms whether you're protected.

Healthcare workers after needlestick injuries, sexual partners of hepatitis B-positive people, and babies born to hepatitis B-positive mothers are the main groups. Nurses, doctors, dentists, lab technicians and cleaners in hospitals face regular occupational exposure risk — needlestick injuries are the most common trigger for PEP. People who share needles for drug use, or who have unprotected sex with a known hepatitis B carrier, also need PEP as soon as possible. Newborns of hepatitis B-positive mothers should get HBIG plus their first vaccine dose within 12 hours of birth — this reduces the mother-to-baby transmission risk from around 90% to under 10%. Anyone in doubt after a possible exposure should treat it as urgent and seek medical assessment; the cost of delayed PEP is chronic hepatitis, which is far harder to manage.

PEP is highly effective when started early — around 85–95% protection against hepatitis B infection if HBIG and vaccine are given within 24 hours. Effectiveness drops the longer treatment is delayed, which is why it's treated as a medical emergency. The exact success rate depends on the type and severity of exposure, the source person's viral load, and the recipient's vaccination status. In healthcare-worker needlestick injuries, PEP prevents the vast majority of infections. For newborns of hepatitis B-positive mothers, timely PEP reduces mother-to-baby transmission risk substantially — from around 20–40% without intervention (rising higher when the mother is HBeAg-positive with high viral load) to under 5%. Follow-up testing at 6 months checks for antibody response and confirms no infection developed. Even in the small number of cases where PEP fails, early detection through follow-up allows prompt treatment and better long-term outcomes.

The core difference is the pathogen: dengue is a virus, malaria is a parasite — and that changes everything downstream. Dengue is caused by any of four serotypes of the dengue virus (DEN-1 to DEN-4), spread by day-biting Aedes mosquitoes. Malaria is caused by Plasmodium parasites (mainly P. falciparum and P. vivax), spread by night-biting Anopheles mosquitoes. Because a virus and a parasite behave differently, the symptoms differ too: malaria produces cyclic fever with chills and sweats, jaundice and anaemia; dengue produces sudden very high fever, pain behind the eyes, rash and a risk of bleeding and shock. Treatment differs completely — malaria has specific parasite-killing drugs; dengue has none, so care is supportive.

Yes — dual infection is uncommon but does happen, especially during monsoon peaks in endemic areas. Both Aedes and Anopheles mosquitoes are active in the same season, and a person can be bitten by both. Co-infection makes diagnosis tricky because symptoms overlap and mask each other; the fever pattern of malaria can be blunted by dengue's rapid onset. Anyone with prolonged fever after mosquito exposure should get tested for both — a malaria smear or RDT plus a dengue NS1/IgM test — instead of assuming only one. Missing one infection while treating the other can be dangerous, especially if platelets are dropping (dengue) while parasites keep multiplying (malaria).

Both can kill, but the danger profile is different — falciparum malaria causes more deaths worldwide; severe dengue kills faster once it turns critical. P. falciparum malaria remains one of the top infectious killers globally, with cerebral malaria and multi-organ failure driving most deaths, especially in children under five. Severe dengue (DHF/DSS) has a lower overall death rate but can go from mild fever to shock within 24 hours during the critical phase around day 3–5, when the fever drops. Both are almost always survivable with prompt hospital care — most deaths from either infection trace back to delayed diagnosis or delayed treatment, not to the pathogen itself being unstoppable.

The five main NANDA-I diagnoses applicable to malaria, in order of priority, are: (1) Hyperthermia — related to systemic response to Plasmodium infection and rupture of erythrocytes releasing pyrogens, as evidenced by temperature above 38.5°C, tachycardia and chills; this is first priority because the cyclical fever spikes (classic 48-hour cycle in P. vivax/ovale, 72-hour in P. malariae) can reach 40–41°C and trigger febrile seizures. (2) Deficient Fluid Volume — related to profuse sweating during fever defervescence, vomiting, and reduced oral intake, as evidenced by dry mucous membranes, decreased urine output and elevated haematocrit; dehydration accelerates haemodynamic compromise. (3) Impaired Tissue Perfusion — related to destruction of red blood cells by the parasite causing haemolytic anaemia, as evidenced by pallor, weakness, and low haemoglobin; in P. falciparum this can progress to cerebral malaria if parasitized cells block cerebral capillaries. (4) Risk for Bleeding — related to thrombocytopaenia (low platelet count) caused by splenic sequestration and immune-mediated platelet destruction; monitor for petechiae, bruising and bleeding gums. (5) Acute Pain — related to myalgia, arthralgia and headache associated with the febrile phase. In GNM/BSc Nursing examinations, always prioritise by Maslow: physiological threats (oxygenation, fluid) before safety, before psychosocial.

The febrile phase of malaria requires concurrent temperature management, fluid replacement, drug administration, and close monitoring — all happening within the same nursing shift. Temperature management: monitor temperature every 1–2 hours during a fever spike; administer paracetamol 650 mg (or as prescribed) for temperature above 38.5°C and document the response; use tepid sponging (30°C water) and a fan; avoid cold water or alcohol sponging (causes shivering and paradoxically raises core temperature). Fluid management: encourage 2–3 litres of oral fluid per day; if the patient is vomiting or obtunded, prepare for IV therapy — Normal Saline or Ringer's Lactate, monitoring intake and output hourly in severe malaria. Antimalarial drug administration: administer as prescribed (Artemisinin-based Combination Therapy — ACT — for P. falciparum; chloroquine or primaquine for P. vivax, with G6PD test required before primaquine to avoid haemolytic reaction); give with food to reduce nausea; do not crush chloroquine tablets. Monitoring: check haemoglobin and platelet count daily in severe malaria; observe for warning signs of cerebral malaria (confusion, seizures, altered GCS) and severe anaemia (Hb below 7 g/dL); check blood glucose in patients on quinine (hypoglycaemia risk); assess urine colour — dark or cola-coloured urine indicates blackwater fever (severe haemolysis) and requires immediate escalation. Document all observations and drug administration times accurately.

Distinguishing severe from uncomplicated malaria is a critical clinical nursing skill because severe malaria requires immediate escalation and IV antimalarials rather than oral ACT. WHO defines severe malaria (almost always P. falciparum) by the presence of one or more of these criteria: (1) Impaired consciousness or unrousable coma — GCS below 10; (2) Prostration — inability to sit up or stand without support in a child who was previously able to; (3) Multiple convulsions — more than 2 within 24 hours; (4) Respiratory distress — deep laboured breathing (acidotic breathing / Kussmaul pattern); (5) Circulatory collapse — systolic BP below 70 mmHg, cold extremities; (6) Abnormal bleeding — spontaneous bleeding from gums, nose or IV sites; (7) Severe anaemia — Hb below 7 g/dL with high parasite density; (8) Haemoglobinuria — dark or black urine without urinary tract infection; (9) Pulmonary oedema confirmed by chest X-ray; (10) Hypoglycaemia — blood glucose below 2.2 mmol/L. Uncomplicated malaria presents with fever, chills, headache, myalgia, vomiting and a positive blood film or RDT — but the patient is conscious, haemodynamically stable, and can tolerate oral medications. Nursing action for severe malaria: immediately notify the physician, prepare IV access, draw blood for FBC, blood glucose, renal and liver function, blood culture, and group and crossmatch; position the patient on their side to protect the airway; have oxygen and emergency resuscitation equipment ready.

Prevention education is essential because malaria relapse (P. vivax has a liver-stage that causes relapse months later) and reinfection are common. Cover five areas: (1) Completing the full drug course — emphasise that stopping antimalarials early because symptoms resolved is the main cause of treatment failure and relapse; for P. vivax, primaquine must be taken for 14 days after the acute phase to eliminate liver-stage parasites (hypnozoites). (2) Mosquito bite prevention — Anopheles mosquitoes bite between dusk and dawn; advise: sleep under a long-lasting insecticidal net (LLIN/ITBN); use DEET-based repellent on exposed skin at night; wear long-sleeved shirts and trousers after sunset; screen windows and doors; eliminate standing water around the home (flowerpots, blocked drains, discarded tyres) where mosquitoes breed. (3) Recognising relapse — P. vivax malaria can recur weeks to months after treatment; teach the patient to seek an RDT or blood smear test if fever with chills returns, and not to self-medicate without confirmation. (4) Travel precautions — if travelling to high-risk areas, take malaria chemoprophylaxis as recommended by a doctor; chemoprophylaxis is different from treatment and must be started before travel. (5) Community role — report suspected cases in the household to the local health worker (ASHA, ANM); indoor residual spraying (IRS) by the health department is a household right in endemic areas.

Everyone aged 50 and above should consider it, and adults 19+ with a weakened immune system are strongly advised to take it. Shingles is caused by reactivation of the varicella-zoster virus that stays dormant after chickenpox infection — around 90% of adults carry it silently. The lifetime risk of developing shingles is roughly 1 in 3, and both risk and severity rise steeply after age 50. Immunocompromised adults (people on chemotherapy, long-term steroids, biologics, HIV, or after organ transplant) can develop shingles much earlier and with worse complications. Anyone who has already had shingles once should still get vaccinated, because recurrence is possible and the vaccine also reduces the risk of postherpetic neuralgia — long-term nerve pain that can last months to years after the rash heals.

Shingrix is a newer, non-live recombinant vaccine that is more effective and safer for immunocompromised people; Zostavax is the older live-virus vaccine. Shingrix is given in two doses 2–6 months apart and offers around 90% protection against shingles and its complications, with efficacy lasting at least 7–10 years. It works in people over 50 and in adults 19+ with a weak immune system. Zostavax is a single-shot live vaccine with lower efficacy (around 51%) that wanes faster; it should not be given to people who are immunocompromised or pregnant. In India both have been available at private hospitals and specialised immunisation centres, though Shingrix availability may vary — check with your doctor about current stock and preferred choice for your health profile.

Yes — Shingrix is recommended for all adults over 50 regardless of chickenpox history, because most adults have already been exposed even if they don't remember. Around 90–99% of adults born before the widespread chickenpox vaccination era carry the varicella-zoster virus silently after childhood exposure. Blood tests for varicella antibodies are not usually needed before Shingrix — the guidance is simply to vaccinate everyone 50+. If someone is confirmed to have never had chickenpox and never been vaccinated against it, they should get the chickenpox vaccine (varicella) first rather than the shingles vaccine, because there's no dormant virus to reactivate — and the two vaccines protect against different clinical situations.

Most side effects are mild and last 1–3 days — sore arm, tiredness, muscle aches, mild fever or headache. Shingrix is known for causing a stronger local reaction than most adult vaccines because of the adjuvant that boosts immune response — around 1 in 6 people feel unwell enough after the shot to skip normal activities for a day or two. This is not dangerous; it's actually a sign the vaccine is working. Symptoms usually settle within 48 hours with rest, fluids and paracetamol. Serious reactions like anaphylaxis are extremely rare. People with a known allergy to any vaccine component should tell their doctor first. The temporary discomfort is far outweighed by the roughly 90% protection against shingles and the misery of postherpetic neuralgia.